PROLASTIN-C, Alpha1-Proteinase Inhibitor
(Human) is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to deficiency of alpha1-proteinase inhibitor
Prolastin, Alpha1-Proteinase Inhibitor
(Human), is indicated for chronic augmentation and maintenance therapy of individuals having congenital deficiency of alpha1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema.
GLASSIA(TM) is the first available ready-to-use liquid alpha1-proteinase inhibitor
(Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.
Grifols leads the global market with its intravenous alpha1-proteinase inhibitor
for the treatment of alpha1-antitrypsin deficiency, a rare disorder that can cause emphysema due to low circulating levels of the alpha1 protein in the lungs.
Grifols is developing its next-generation alpha1-proteinase inhibitor
as an inhaled formulation.
Glassia is a unique, high purity, ready-to-use liquid alpha- 1 proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor
, also known as alpha-1 antitrypsin deficiency (AATD).
Indications: For long-term augmentation therapy in patients with alpha1-proteinase inhibitor
deficiency (genotype PiZZ, PiZ-Null, PiNull-Null, and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).
The effect of augmentation therapy with any alpha1-proteinase inhibitor
(A1PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.